Table 1.
Baseline characteristics of the included hemodialysis patients by time of booster dosing: after the 6th month assessment (late booster) and before the 6th month assessment (early booster)
| Total N = 711 | Late booster N = 166 | Early booster N = 545 | P | ||
|---|---|---|---|---|---|
| Sex (male), n (%) | 475 (66.8) | 113 (68.1) | 362 (66.4) | .623 | |
| Age (years), median (range) | 67 (20–89) | 68 (27–86) | 67 (20–89) | .316 | |
| Diabetic kidney disease, n (%) | 212 (29.8) | 53 (31.9) | 159 (29.2) | .497 | |
| Hemodialysis technique, n (%) | |||||
| HFHD | 321 (45.2) | 84 (50.6) | 237 (43.6) | .226 | |
| HDx | 36 (5.1) | 6 (3.6) | 30 (5.5) | ||
| OL-HDF | 353 (49.7) | 76 (45.8) | 277 (50.9) | ||
| Vascular access, n (%): | |||||
| AVF | 469 (67.4) | 103 (62.4) | 366 (68.9) | .119 | |
| Catheter | 227 (32.6) | 62 (37.6) | 165 (31.1) | ||
| Anticoagulants, n (%) | 113 (15.9) | 33 (19.9) | 80 (14.7) | .109 | |
| Antiplatelet agents, n (%) | 294 (41.4) | 63 (38.0) | 231 (42.4) | .310 | |
| RAASi, n (%) | 237 (33.3) | 60 (36.1) | 177 (32.5) | .380 | |
| ESA, n (%) | 536 (75.4) | 116 (69.9) | 420 (77.1) | .060 | |
| Vaccine (initial), n (%) | |||||
| BNT162b2 | 233 (32.8) | 78 (47.0) | 155 (28.4) | .001 | |
| mRNA-1273 | 471 (66.2) | 86 (51.8) | 385 (70.6) | ||
| ChAdOx1-S | 4 (0.6) | 2 (1.2) | 2 (0.4) | ||
| Ad26.COV.2 | 3 (0.4) | 0 (0.0) | 3 (0.6) | ||
| Vaccine (booster dose), n (%): | |||||
| BNT162b2 | 230 (32.3) | 82 (49.4) | 148 (27.2) | .001 | |
| mRNA-1273 | 481 (67.7) | 84 (50.6) | 397 (72.8) | ||
| COVID-19 before vaccination, n (%) | 83 (11.7) | 19 (11.4) | 64 (11.7) | .917 | |
Data are presented as n (%), unless otherwise noted. ESA, erythropoiesis stimulating agent; HD, hemodialysis; HFHD, high flux hemodialysis; HDx, expanded hemodialysis therapy; OL-HDF, online hemodiafiltration; AVF, arteriovenous fistulae; RAASi, renin–angiotensin–aldosterone inhibitors; COVID-19: coronavirus disease 2019.